ArticleCureus2026
Mixed Invasive Adenoid Cystic and Lobular Carcinoma of the Breast: A Case Report of a Rare Hybrid Tumor.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoid cystic carcinoma (ACC) of the breast is an exceedingly rare subtype of triple-negative breast cancer, accounting for less than 0.1% of all breast malignancies. In contrast, invasive lobular carcinoma (ILC) is a more common special histologic type, comprising 5-15% of breast cancers and typically characterized by estrogen receptor positivity and complete loss of epithelial cadherin (E-cadherin) expression. The coexistence of these two biologically and morphologically distinct neoplasms within the same breast lesion is exceptionally rare and, to our knowledge, has not been previously documented. A 62-year-old Caucasian female patient presented with nonspecific stinging discomfort in the right breast. Diagnostic imaging revealed a 1.8 cm irregular, spiculated mass. A core needle biopsy demonstrated invasive mammary carcinoma that was estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor receptor 2 (HER2)-negative. Following right breast mastectomy and sentinel lymph node biopsy, final pathology revealed a biphasic neoplasm composed of both ACC and lobular carcinoma (LC) components. The ACC component exhibited classic cribriform and tubular architecture, a triple-negative immunophenotype, strong transformation-related protein 63 (p63) and cluster of differentiation 117 (CD117; c-Kit) positivity, and a low Ki-67 proliferation index (9.8%). The LC component lacked a classic single-file growth pattern but showed dyscohesive cell clusters with complete loss of E-cadherin expression, strong estrogen receptor positivity (94.18%), and a markedly elevated Ki-67 index (42.9%). All seven sentinel lymph nodes were negative for metastatic carcinoma. This rare case of synchronous ACC and ILC underscores the diagnostic complexity of composite breast tumors. Accurate classification requires careful correlation of histomorphology with immunohistochemical findings, particularly when one or both components exhibit non-classical architectural patterns. Given the contrasting biological behavior of triple-negative ACC and hormone receptor-positive ILC, an individualized, multidisciplinary management strategy is essential. Increased awareness of such mixed neoplasms may enhance diagnostic precision and improve patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.